EOHILIA™ (budesonide oral suspension) is an FDA approved 12-week oral treatment for EoE in people 11 years and older. It has not been shown to be safe and effective for longer than 12 …

How Was Eohilia Studied for the Treatment of EoE? Eohilia was studied in two clinical trials involving people aged 11 and older who have EoE.

Nov 26, 2025 · Eohilia (budesonide) suspension is used to treat eosinophilic esophagitis (EoE), to reduce symptoms and improve the ability to swallow. Includes dose, side effects, interactions …

Indication and Limitations of Use EOHILIA (budesonide oral suspension) is indicated for 12 weeks of treatment in adult and pediatric patients 11 years of age and older with eosinophilic …

Feb 12, 2024 · FDA Approves Takeda’s EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE)

EOHILIA is a corticosteroid indicated for 12 weeks of treatment in adult and pediatric patients 11 years of age and older with eosinophilic esophagitis (EoE). (1)

Mar 17, 2025 · Historically, treatment options for EoE have been limited, often relying on proton pump inhibitors (PPIs), dietary modifications, and off-label use of medications such as …

Numan L, Kalot MA, Brotherton T, Tarakji A, Hamdeh S. Comparison of viscous budesonide and fluticasone in the treatment of patients with eosinophilic esophagitis: a systematic review and …

EOHILIA is the first and only 12-week, FDA-approved oral treatment designed for people with eosinophilic esophagitis (EoE) 11 years and older. It is a liquid-like form of budesonide …

Feb 12, 2024 · EOHILIA is a corticosteroid indicated for 12 weeks of treatment in patients 11 years and older with EoE. 1 Developed specifically for EoE, EOHILIA’s novel formulation of …